A novel platinum-based chemotherapeutic inducing immunogenic cell death

Figures & data

Figure 1. Immunogenic cell death inducer discovery. Drugs that are endowed with the capacity to elicit immunogenic cell death (ICD) can be advantageously combined with immune checkpoint blockade. Thus, the identification of ICD-inducing agents can be driven by “illustrated serendipity”, which is based on findings from clinical (and preclinical) studies depicting improved outcome when the candidate ICD inducer is combined with immune checkpoint blockade (ICB). Alternatively, systems biology approaches can be employed, that predict (based on physical and chemical drug properties) and measure the emission of ICD hallmarks as an indication for the capacity to elicit anticancer immunity. Prospective ICD inducers can be further validated and combined with ICB in immunocompetent animal models